Aug 7, 2017 8:00 am EDT AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors
Jul 17, 2017 8:00 am EDT AntriaBio Announces $13 Million Close of Private Placement Transaction and Plan to Dose First Patient with AB101 This Month
Jun 5, 2017 8:00 am EDT AntriaBio Files Investigational New Drug Application for Once-Weekly Basal Insulin AB101
May 1, 2017 8:00 am EDT AntriaBio Formally Engages CRO for the Conduct of its Phase I First-in-Human Clinical Trial of AB101
Dec 15, 2016 5:15 pm EST AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
Sep 22, 2016 8:00 am EDT AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
